A quantitative analysis of research publications focused on the top chief complaints in patients with skin of color

A quantitative analysis of research publications focused on skin of color: Representation in academic dermatology journals

“…Similar to the findings of Montgomery and Elbuluk, 1 the SoC publications comprised a minuscule proportion of the total publications (377/11,003, 3.4%), with no substantial changes throughout 2015-2019 (Fig 2). The Journal of the American Academy Our study indicated that little progress has been made to increase SoC in the literature.…”

“…Dermatology organizations, such as the SoC Society, advocate for SoC awareness, education, networking, and even provide grants for physicians in SoC-focused research. Along with Montgomery and Elbuluk, 1 we emphasize the need for increased inclusivity within the academic literature, and dermatologists should therefore take advantage of this opportunity to investigate and publish in SoC.…”

“…To the Editor: We commend Montgomery and Elbuluk 1 for highlighting the shortage of publications focused on the top chief complaints in Skin of Color (SoC) patients, as there remains a disproportionate representation of SoC patients in dermatologic literature. We aimed to augment their findings with a survey of SoC representation in the top dermatology journals.…”

Acne and rosacea in skin of colour

“…Cultural practices such as the use of skin‐lightening creams may also precipitate the development of both conditions. There is a paucity of peer‐reviewed literature on the management of both skin conditions in SOC and a shortage of participant diversity in research studies 23 . Further research and clinical trials including patients with SOC is essential to develop an individualized therapeutic approach.…”

Assessment and Monitoring Challenges Among Patients With Moderate-to-Severe Atopic Dermatitis Across Fitzpatrick Skin Types: A Photographic Review and Case Series

“…Accurate assessment of AD disease severity is also crucial to ensure the scientific integrity of clinical trials, given that the EASI is a core outcome measure and the Validated Investigator Global Assessment for AD (vIGA-AD) is based on clinical signs of the disease, including erythema. It is also important to enroll sufficient numbers of patients with SOC into AD clinical trials to ensure adequate statistical power to identify potential differences in response to treatment among specific racial/ethnic populations, something that has been lacking historically 54 . Selection of clinical research organizations, clinical trial investigators, and groups that have an informed understanding of the need for more diversity in clinical trials is critically important.…”